Compare Corning Incorporated (GLW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Sanofi SA — how do they compare? Corning Incorporated trades at $156.69 (market cap $131.65B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Corning Incorporated is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Sanofi SA for 94 Days on average.
| GLW | SNY | |
|---|---|---|
Market Cap | $131.65B | $95.18B |
Volume | 8,992,522 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $255.79 | $52.34 |
52-Week Low | $78.03 | $39.51 |
Typical Hold Time | 36 Days | 94 Days |
Enterprise Value | $138.52B | $114.48B |
Dividend Yield | 0.73% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $152.81, down 6.37% amid a bearish technical signal, though it recently secured a significant $3 billion fiber supply deal with AT&T. The company shows strong earnings momentum with three consecutive quarterly beats and improved 2025 financials, including revenue growth to $15.63B and net income of $1.60B. Valuation ratios remain elevated with a P/E of 70.43, while analyst consensus is bullish with a $171.25 price target.
The outlook is mixed: the AT&T deal and earnings strength support growth, but high valuation and a bearish technical picture pose risks. Investors should weigh the company's positioning in AI-driven infrastructure against potential volatility from patent litigation and competitive pressures.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
